News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter

PharmStar Pharmaceuticals, Inc. CEO to Appear on the Bill Chippas Show

10/25/2011 8:37:30 AM

WILSON, NC--(Marketwire - October 25, 2011) -

PharmStar Pharmaceuticals, Inc. (PINKSHEETS: PHAR) (the "Company"), a U.S. drug developer, manufacturer and marketer of the FDA-approved, Over-the-Counter (OTC) liquid pain reliever Aquaprin™, announced today that its Chief Executive Officer, Howard Phykitt, will be interviewed on the Bill Chippas Show on Tuesday, October 25, 2011 from 10:00 am to 11:00 am Eastern Time. Those interested in PharmStar Pharmaceuticals are encouraged to listen live tomorrow at 10 am ET by visiting or

Mr. Phykitt is the inventor of Aquaprin, the signature pain reliever that is being commercialized for distribution by PharmStar. He will provide a summary of the Company's recent developments, which include:

  • The recent restructuring of the Company's capital formation
  • Initial distribution agreement for Aquaprin
  • Election of Dr. James Carlson to the Board of Directors and Medical Advisory Board

Mr. Phykitt will take questions from callers during his segment on the show. Callers can talk with Mr. Phykitt by calling 1-772-220-9788 or email questions during the show to

Since 2005, Bill has hosted the Bill Chippas Show in South Florida on AM 1590 and AM 1450. Individual investors, active traders and institutional professionals rely on Bill's timely, unbiased analysis, deep rooted market background and experience spanning four decades to make intelligent and common sense investments. Bill's weekly Stock Market Comments appear in Weekly Market Strategies delivered by Princeton Research ( to global investors, and Bill's opinion columns appear in In 1996, Bill founded FuturesCom, which remains one of today's longest running Internet-based, independent publications for investment market research. To learn more about Bill, visit

About PharmStar Pharmaceuticals
PharmStar Pharmaceuticals, Inc. is a U.S.-based drug development, manufacturing and marketing company and the innovator of Aquaprin™, an FDA-approved Over-the-Counter (OTC) liquid pain reliever. In development since 1993 with over $3 million invested to-date, Aquaprin™ is a liquid derivative of aspirin based on a patent-pending formula. The product is designed to dissolve nearly instantly in just 1.5 ounces of water, which can be absorbed into the bloodstream up to 10 times faster than traditional OTC pain relievers, and with little to no stomach upset. PharmStar's headquarters are located in Rocky Mount, NC. For more information, visit

Forward-Looking Statements Disclosure
This press release includes "forward-looking statements" within the meaning of the federal securities laws, commonly identified by such terms as "believes," "will," "looking ahead," "anticipates," "estimates" and other terms with similar meaning. Although the Company believes that the assumptions upon which its forward-looking statements are based are reasonable, it can give no assurance that these assumptions will prove to be correct.

PharmStar, Inc.
Investor Contact:

Read at

comments powered by Disqus